Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer

Providing Protocol Information for Journal of Clinical Oncology Readers: What Practicing Clinicians Need to Know

(2011) Daniel G. Haller et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past

(2010) C. M. Booth   CLINICAL CANCER RESEARCH

Translating Clinical Trials into Meaningful Outcomes

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

(2010) T. Fojo et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Trials: Inevitable or Inadvisable?

(2010) Hui K. Gan et al.   JOURNAL OF CLINICAL ONCOLOGY

Equipoise Lost: Ethics, Costs, and the Regulation of Cancer Clinical Research

(2010) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

When Are "Positive" Clinical Trials in Oncology Truly Positive?

(2010) A. Ocana et al.   JNCI-Journal of the National Cancer Institute

Sample size re-estimation in clinical trials

(2009) Michael A. Proschan   BIOMETRICAL JOURNAL

Incremental Advance or Seismic Shift? The Need to Raise the Bar of Efficacy for Drug Approval

(2009) Alberto Sobrero et al.   JOURNAL OF CLINICAL ONCOLOGY

Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics

(2009) Laurent Claret et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Trials in Oncology Stopped Early for Benefit

(2007) Ryan A. Wilcox et al.   JOURNAL OF CLINICAL ONCOLOGY